Inhibiting the alarmin-driven hematopoiesis-stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis.
Saved in:
| Title: | Inhibiting the alarmin-driven hematopoiesis-stromal cell crosstalk in primary myelofibrosis ameliorates bone marrow fibrosis. |
|---|---|
| Authors: | Gleitz HFE; Department of Developmental Biology Erasmus Medical Center Rotterdam The Netherlands.; Oncode Institute Erasmus Medical Center Cancer Institute Rotterdam The Netherlands.; Department of Cell and Tumor Biology, Faculty of Medicine University Hospital RWTH Aachen Aachen Germany., Fuchs SNR; Department of Developmental Biology Erasmus Medical Center Rotterdam The Netherlands.; Oncode Institute Erasmus Medical Center Cancer Institute Rotterdam The Netherlands., Snoeren IAM; Department of Developmental Biology Erasmus Medical Center Rotterdam The Netherlands.; Oncode Institute Erasmus Medical Center Cancer Institute Rotterdam The Netherlands., Boys C; Institute for Computational Biomedicine, Faculty of Medicine, and Heidelberg University Hospital Heidelberg University Heidelberg Germany., Nagai J; Institute for Computational Genomics, Faculty of Medicine RWTH Aachen University Aachen Germany., Tejeda-Mora H; Department of Developmental Biology Erasmus Medical Center Rotterdam The Netherlands.; Oncode Institute Erasmus Medical Center Cancer Institute Rotterdam The Netherlands., Klöker V; Institute for Computational Genomics, Faculty of Medicine RWTH Aachen University Aachen Germany., Pritchard JE; Department of Developmental Biology Erasmus Medical Center Rotterdam The Netherlands.; Oncode Institute Erasmus Medical Center Cancer Institute Rotterdam The Netherlands.; Department of Cell and Tumor Biology, Faculty of Medicine University Hospital RWTH Aachen Aachen Germany., Bakker IJ; Department of Developmental Biology Erasmus Medical Center Rotterdam The Netherlands., Gargallo Garasa M; Department of Developmental Biology Erasmus Medical Center Rotterdam The Netherlands.; Oncode Institute Erasmus Medical Center Cancer Institute Rotterdam The Netherlands., Bindels E; Department of Hematology Erasmus Medical Center Cancer Institute Rotterdam The Netherlands., Saez-Rodriguez J; Institute for Computational Biomedicine, Faculty of Medicine, and Heidelberg University Hospital Heidelberg University Heidelberg Germany., Vogl T; Institute of Immunology University of Münster Münster Germany., Kramann R; Institute of Experimental Medicine and Systems Biology, Medical Faculty RWTH Aachen University Aachen Germany.; Division of Nephrology and Clinical Immunology, Medical Faculty RWTH Aachen University Aachen Germany.; Department of Internal Medicine, Nephrology and Transplantation Erasmus Medical Center Rotterdam The Netherlands., Dugourd A; Institute for Computational Biomedicine, Faculty of Medicine, and Heidelberg University Hospital Heidelberg University Heidelberg Germany., Costa IG; Institute for Computational Genomics, Faculty of Medicine RWTH Aachen University Aachen Germany., Schneider RK; Department of Developmental Biology Erasmus Medical Center Rotterdam The Netherlands.; Oncode Institute Erasmus Medical Center Cancer Institute Rotterdam The Netherlands.; Department of Cell and Tumor Biology, Faculty of Medicine University Hospital RWTH Aachen Aachen Germany. |
| Source: | HemaSphere [Hemasphere] 2025 Aug 14; Vol. 9 (8), pp. e70179. Date of Electronic Publication: 2025 Aug 14 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!